11 articles
Aceclidine
Aceclidine: a cholinergic muscarinic agonist miotic, long approved in Europe for glaucoma; approved in the US July 31, 2025 as VIZZ 1.44% (LNZ100, LENZ Therapeutics), a once-daily drop for adult presbyopia.
ALLEGRO-2b/3 trial
ALLEGRO-2b/3 (NCT03732807), Pfizer's pivotal phase 2b/3 trial of ritlecitinib (PF-06651600, Litfulo) for severe alopecia areata in patients 12 and older; 718 randomized, SALT ≤20 primary endpoint at week 24.
Ambenonium
Ambenonium (Mysuran, Mytelase) is a quaternary ammonium, reversible acetylcholinesterase inhibitor introduced in 1955 for myasthenia gravis; longer-acting and more potent than neostigmine, now a second-line option for pyridostigmine-intolerant patients.
Bimatoprost grenod
Bimatoprost grenod (NCX 470, K-911) is a nitric oxide-donating bimatoprost eye drop for open-angle glaucoma and ocular hypertension; two positive phase 3 trials and an FDA-accepted NDA with April 2027 PDUFA date.
Compound Binafuxi granules
Compound Binafuxi granules (复方比那甫西颗粒) is a Class 1.1 innovative Uyghur-medicine TCM approved by China's NMPA in February 2025 for heat-type common cold; six-herb formula by Xinjiang Yinduolan, national insurance listed 2026.
Cridanimod
Cridanimod (Cycloferon, Neovir) is an acridone small-molecule immunomodulator, ATC L03AX18, that induces interferon alpha/beta and progesterone receptor expression; investigated in phase 2 endometrial cancer trials, no FDA approval.
Elamipretide
Elamipretide (SS-31, MTP-131, Bendavia, Forzinity) is a cardiolipin-binding mitochondria-targeting tetrapeptide, D-Arg-Dmt-Lys-Phe-NH2; FDA accelerated approval 2025 for Barth syndrome, negative MMPOWER-3 trial in mitochondrial myopathy.
Filgotinib
Filgotinib (Jyseleca, GS-6034/GLPG0634) is an oral preferential JAK1 inhibitor approved in the EU, UK, and Japan for rheumatoid arthritis and ulcerative colitis, dosed once daily as 100 or 200 mg maleate tablets.
Propiverine
Propiverine (Mictonorm, Mictoryl) is an antimuscarinic and calcium-antagonistic detrusor relaxant for overactive bladder, neurogenic detrusor overactivity, and male storage LUTS, dosed 15 mg IR twice daily or 30–45 mg ER once daily.
Resatorvid
Resatorvid (TAK-242, CLI-095) is a small-molecule TLR4 inhibitor binding Cys747 in the intracellular TIR domain, blocking TIRAP/TRAM adaptor interactions. Reached phase 3 for severe sepsis but failed to reduce cytokines or mortality; now a research tool.
Terevalefim
Terevalefim (ANG-3777, Refanalin, SNV-003) is an investigational small-molecule HGF mimetic and c-Met agonist from Angion Biomedica, in phase 3 trials for delayed graft function; COVID-19 and cardiac-surgery AKI trials missed endpoints.